Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT).

Schoeny R, Cross KP, DeMarini DM, Elespuru R, Hakura A, Levy DD, Williams RV, Zeiger E, Escobar PA, Howe JR, Kato M, Lott J, Moore MM, Simon S, Stankowski LF Jr, Sugiyama KI, van der Leede BM.

Mutat Res. 2020 Jan;849:503137. doi: 10.1016/j.mrgentox.2020.503137. Epub 2020 Jan 13.

PMID:
32087853
2.

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.

Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.2884.2019. doi: 10.1158/1078-0432.CCR-19-2884. [Epub ahead of print]

PMID:
31937620
3.

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF.

Pancreas. 2020 Jan;49(1):1-33. doi: 10.1097/MPA.0000000000001454.

PMID:
31856076
4.

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids.

Ear PH, Li G, Wu M, Abusada E, Bellizzi AM, Howe JR.

J Vis Exp. 2019 Oct 14;(152). doi: 10.3791/60303.

PMID:
31657801
5.

Discordant findings on preoperative imaging for primary hyperparathyroidism and thyroid disease: Choosing the path to follow.

Beck AC, Kashyap AK, Lal G, Howe JR, Weigel RJ, Graham MM, Sugg SL.

Surgery. 2019 Oct;166(4):678-685. doi: 10.1016/j.surg.2019.05.057. Epub 2019 Aug 27.

PMID:
31466855
6.

Evaluation and Management of Neuroendocrine Tumors of the Pancreas.

Scott AT, Howe JR.

Surg Clin North Am. 2019 Aug;99(4):793-814. doi: 10.1016/j.suc.2019.04.014. Epub 2019 May 27. Review.

PMID:
31255207
7.

The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.

Scott AT, Pelletier D, Maxwell JE, Sherman SK, Keck KJ, Li G, Dillon JS, O'Dorisio TM, Bellizzi AM, Howe JR.

Ann Surg Oncol. 2019 Aug;26(8):2525-2532. doi: 10.1245/s10434-019-07370-3. Epub 2019 Apr 22.

PMID:
31011904
8.

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE.

J Clin Invest. 2019 Mar 4;130:1641-1653. doi: 10.1172/JCI123049. eCollection 2019 Mar 4.

9.

Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).

Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR.

Surgery. 2019 Jan;165(1):166-175. doi: 10.1016/j.surg.2018.04.070. Epub 2018 Oct 19.

10.

Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E.

Semin Oncol. 2018 Aug;45(4):232-235. doi: 10.1053/j.seminoncol.2018.07.002. Epub 2018 Oct 11. Review.

PMID:
30318110
11.

The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.

Goffredo P, Utria AF, Beck AC, Chun YS, Howe JR, Weigel RJ, Vauthey JN, Hassan I.

J Gastrointest Surg. 2019 Oct;23(10):1957-1963. doi: 10.1007/s11605-018-3978-4. Epub 2018 Oct 1.

PMID:
30276588
12.

Radioguided Surgery With Gallium for Neuroendocrine Tumors.

Howe JR.

JAMA Surg. 2019 Jan 1;154(1):45-46. doi: 10.1001/jamasurg.2018.3480. No abstract available.

PMID:
30267062
13.

The mouse as a model for neuropsychiatric drug development.

Howe JR 6th, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ.

Curr Biol. 2018 Sep 10;28(17):R909-R914. doi: 10.1016/j.cub.2018.07.046.

14.

Risk factors for 30-day readmission after adrenalectomy.

Beck AC, Goffredo P, Hassan I, Sugg SL, Lal G, Howe JR, Weigel RJ.

Surgery. 2018 Oct;164(4):766-773. doi: 10.1016/j.surg.2018.04.041. Epub 2018 Aug 7.

15.

Management of Small Bowel Neuroendocrine Tumors.

Scott AT, Howe JR.

J Oncol Pract. 2018 Aug;14(8):471-482. doi: 10.1200/JOP.18.00135. Review.

16.

Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.

Levy AD, Xiao X, Shaw JE, Sudarsana Devi SP, Katrancha SM, Bennett AM, Greer CA, Howe JR, Machida K, Koleske AJ.

Cell Rep. 2018 Aug 7;24(6):1523-1535. doi: 10.1016/j.celrep.2018.07.006.

17.

The Distal Predilection of Small Bowel Neuroendocrine Tumors.

Keck KJ, Maxwell JE, Utria AF, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2018 Oct;25(11):3207-3213. doi: 10.1245/s10434-018-6676-2. Epub 2018 Jul 27.

18.

Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.

Czeczok TW, Stashek KM, Maxwell JE, O'Dorisio TM, Howe JR, Hornick JL, Bellizzi AM.

Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):94-100. doi: 10.1097/PAI.0000000000000563.

19.

Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases.

Keck KJ, Breheny P, Braun TA, Darbro B, Li G, Dillon JS, Bellizzi AM, O'Dorisio TM, Howe JR.

Surgery. 2018 Jan;163(1):232-239. doi: 10.1016/j.surg.2017.07.031. Epub 2017 Nov 16.

20.

Injection of bulking agents for laryngoplasty.

Snyder SK, Angelos P, Carty SE, Doherty GM, Howe JR, Lee JA, Libutti SK, Miller BS, Parangi S, Patel KN, Sippel RC, Sturgeon C, Wang TS, Yip L, Zeiger MA.

Surgery. 2018 Jan;163(1):6-8. doi: 10.1016/j.surg.2017.08.019. Epub 2017 Nov 9. No abstract available.

PMID:
29129367
21.

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR.

J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. No abstract available.

22.

Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Choi AB, Maxwell JE, Keck KJ, Bellizzi AJ, Dillon JS, OʼDorisio TM, Howe JR.

Pancreas. 2017 Oct;46(9):1115-1120. doi: 10.1097/MPA.0000000000000911.

23.

Unitary Properties of AMPA Receptors with Reduced Desensitization.

Zhang W, Eibl C, Weeks AM, Riva I, Li YJ, Plested AJR, Howe JR.

Biophys J. 2017 Nov 21;113(10):2218-2235. doi: 10.1016/j.bpj.2017.07.030. Epub 2017 Aug 30.

24.

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF.

Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. Review.

25.

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK.

Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. Review.

26.

Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.

Keck KJ, Choi A, Maxwell JE, Li G, O'Dorisio TM, Breheny P, Bellizzi AM, Howe JR.

Ann Surg Oncol. 2017 Aug;24(8):2206-2212. doi: 10.1245/s10434-017-5899-y. Epub 2017 May 30.

27.

MiR-338-3p regulates neuronal maturation and suppresses glioblastoma proliferation.

Howe JR 6th, Li ES, Streeter SE, Rahme GJ, Chipumuro E, Russo GB, Litzky JF, Hills LB, Rodgers KR, Skelton PD, Luikart BW.

PLoS One. 2017 May 11;12(5):e0177661. doi: 10.1371/journal.pone.0177661. eCollection 2017.

28.

Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.

Lee JP, Hung YP, O'Dorisio TM, Howe JR, Hornick JL, Bellizzi AM.

Histopathology. 2017 Oct;71(4):503-510. doi: 10.1111/his.13243. Epub 2017 Jul 13.

29.

Juvenile Polyposis Syndrome.

Larsen Haidle J, Howe JR.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
2003 May 13 [updated 2017 Mar 9].

30.

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.

Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS.

J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2.

31.

Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease.

Wu VT, Lorenzen AW, Beck AC, Reid VJ, Sugg SL, Howe JR, Pollard JH, Lal G, Weigel RJ.

Surgery. 2017 Jan;161(1):147-155. doi: 10.1016/j.surg.2016.06.066. Epub 2016 Nov 15.

32.

Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.

Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR.

Surgery. 2017 Jan;161(1):272-279. doi: 10.1016/j.surg.2016.05.055. Epub 2016 Nov 15.

33.

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR.

Pancreas. 2017 Feb;46(2):151-156. doi: 10.1097/MPA.0000000000000734.

34.

Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.

Maxwell JE, Sherman SK, Howe JR.

Clin Cancer Res. 2016 Oct 15;22(20):5022-5029. Review.

35.

Distinct Subunit Domains Govern Synaptic Stability and Specificity of the Kainate Receptor.

Straub C, Noam Y, Nomura T, Yamasaki M, Yan D, Fernandes HB, Zhang P, Howe JR, Watanabe M, Contractor A, Tomita S.

Cell Rep. 2016 Jul 12;16(2):531-544. doi: 10.1016/j.celrep.2016.05.093. Epub 2016 Jun 23.

36.

Train stimulation of parallel fibre to Purkinje cell inputs reveals two populations of synaptic responses with different receptor signatures.

Devi SP, Howe JR, Auger C.

J Physiol. 2016 Jul 1;594(13):3705-27. doi: 10.1113/JP272415. Epub 2016 May 29.

37.

Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor.

Van Dyke TJ, Johlin FC, Bellizzi AM, Howe JR.

Dig Surg. 2016;33(3):240-8. doi: 10.1159/000444721. Epub 2016 Mar 22. Review.

38.

Neto2 Influences on Kainate Receptor Pharmacology and Function.

Han L, Howe JR, Pickering DS.

Basic Clin Pharmacol Toxicol. 2016 Aug;119(2):141-8. doi: 10.1111/bcpt.12575. Epub 2016 Mar 18. Review.

39.

Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Maxwell JE, O'Dorisio TM, Howe JR.

Surg Oncol Clin N Am. 2016 Jan;25(1):171-94. doi: 10.1016/j.soc.2015.08.008. Epub 2015 Oct 31. Review.

40.

Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.

Maxwell JE, Sherman SK, Li G, Choi AB, Bellizzi AM, O'Dorisio TM, Howe JR.

Cancer Genet. 2015 Sep 15. pii: S2210-7762(15)00184-2. doi: 10.1016/j.cancergen.2015.08.003. [Epub ahead of print]

41.

Auxiliary subunits highlight a role for the LBD-TMD linkers in glutamate receptor desensitization.

Howe JR.

J Physiol. 2015 Nov 15;593(22):4813-4. doi: 10.1113/JP271434. No abstract available.

42.

Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR.

Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9.

43.

Imaging in neuroendocrine tumors: an update for the clinician.

Maxwell JE, Howe JR.

Int J Endocr Oncol. 2015;2(2):159-168.

44.

FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders.

Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, Amenduni M, Szekely A, Palejev D, Wilson M, Gerstein M, Grigorenko EL, Chawarska K, Pelphrey KA, Howe JR, Vaccarino FM.

Cell. 2015 Jul 16;162(2):375-390. doi: 10.1016/j.cell.2015.06.034.

45.

The Supporting Role of (18)FDG-PET in Patients with Neuroendocrine Tumors.

Howe JR.

Ann Surg Oncol. 2015 Jul;22(7):2107-9. doi: 10.1245/s10434-015-4484-5. Epub 2015 Mar 17. No abstract available.

PMID:
25777088
46.

Modulation of non-NMDA receptor gating by auxiliary subunits.

Howe JR.

J Physiol. 2015 Jan 1;593(1):61-72. doi: 10.1113/jphysiol.2014.273904. Epub 2014 Sep 22. Review.

47.

Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.

Sherman SK, Maxwell JE, Qian Q, Bellizzi AM, Braun TA, Iannettoni MD, Darbro BW, Howe JR.

Cancer Genet. 2015 Jan-Feb;208(1-2):41-6. doi: 10.1016/j.cancergen.2014.11.002. Epub 2014 Nov 15.

48.

A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Maxwell JE, Sherman SK, Stashek KM, O'Dorisio TM, Bellizzi AM, Howe JR.

Surgery. 2014 Dec;156(6):1359-65; discussion 1365-6. doi: 10.1016/j.surg.2014.08.008. Epub 2014 Nov 11.

49.

Stargazin promotes closure of the AMPA receptor ligand-binding domain.

MacLean DM, Ramaswamy SS, Du M, Howe JR, Jayaraman V.

J Gen Physiol. 2014 Dec;144(6):503-12. doi: 10.1085/jgp.201411287.

50.

RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, Gourronc FA, Klingelhutz AJ, Major HJ, Askeland RW, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR, Darbro BW, Quelle DE.

Cancer Res. 2014 Nov 15;74(22):6661-70. doi: 10.1158/0008-5472.CAN-13-3742. Epub 2014 Oct 1.

Supplemental Content

Support Center